Literature DB >> 10363966

A new cis element is involved in the HER2 gene overexpression in human breast cancer cells.

M Grooteclaes1, D Vernimmen, S Plaza, F Pasleau, D Hodzic, R Winkler-Gol.   

Abstract

The HER2 proto-oncogene product is overexpressed in 30% of breast cancers, and this correlates with poor prognosis. Increased levels of HER2 mRNA in breast cancer cell lines result from increased gene transcription. We report the identification of a new 17-bp-long cis sequence located between positions -506 and -489 from the transcription start site. This sequence is recognized by a trans-activating factor that we tentatively named HER2 transcription factor (HTF). This factor, involved in the increased transcription of the HER2 gene in the BT-474 mammary tumor cells, has a molecular weight of about Mr 50,000. HTF can also bind, but with a lower affinity, to a related cis sequence present in the epidermal growth factor receptor promoter. Interestingly, the HTF binding activity is high in nuclear extracts from several mammary tumor cells overexpressing the HER2 gene.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10363966

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  7 in total

1.  Chromatin modifications sequentially enhance ErbB2 expression in ErbB2-positive breast cancers.

Authors:  Sathish Kumar Mungamuri; William Murk; Luca Grumolato; Emily Bernstein; Stuart A Aaronson
Journal:  Cell Rep       Date:  2013-10-10       Impact factor: 9.423

2.  Identification of HTF (HER2 transcription factor) as an AP-2 (activator protein-2) transcription factor and contribution of the HTF binding site to ERBB2 gene overexpression.

Authors:  Douglas Vernimmen; Dominique Begon; Christophe Salvador; Stéphanie Gofflot; Madeleine Grooteclaes; Rosita Winkler
Journal:  Biochem J       Date:  2003-02-15       Impact factor: 3.857

3.  Transcription factor gene AP-2 gamma essential for early murine development.

Authors:  Uwe Werling; Hubert Schorle
Journal:  Mol Cell Biol       Date:  2002-05       Impact factor: 4.272

Review 4.  The role of HER2 in early breast cancer metastasis and the origins of resistance to HER2-targeted therapies.

Authors:  Jaclyn A Freudenberg; Qiang Wang; Makoto Katsumata; Jeffrey Drebin; Izumi Nagatomo; Mark I Greene
Journal:  Exp Mol Pathol       Date:  2009-05-18       Impact factor: 3.362

5.  Ku proteins interact with activator protein-2 transcription factors and contribute to ERBB2 overexpression in breast cancer cell lines.

Authors:  Grégory Nolens; Jean-Christophe Pignon; Benjamin Koopmansch; Benaïssa Elmoualij; Willy Zorzi; Edwin De Pauw; Rosita Winkler
Journal:  Breast Cancer Res       Date:  2009-11-11       Impact factor: 6.466

6.  The combined immunodetection of AP-2alpha and YY1 transcription factors is associated with ERBB2 gene overexpression in primary breast tumors.

Authors:  Abdelkader Allouche; Gregory Nolens; Annalisa Tancredi; Laurence Delacroix; Julie Mardaga; Viviana Fridman; Rosita Winkler; Jacques Boniver; Philippe Delvenne; Dominique Y Begon
Journal:  Breast Cancer Res       Date:  2008-01-24       Impact factor: 6.466

7.  Different mechanisms are implicated in ERBB2 gene overexpression in breast and in other cancers.

Authors:  D Vernimmen; M Gueders; S Pisvin; P Delvenne; R Winkler
Journal:  Br J Cancer       Date:  2003-09-01       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.